| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -680 | -19,810 | -2,210 | -2,260 | -1,420 |
| Net Income Growth | +96.57% | -796.38% | +2.21% | -59.16% | +40.83% |
Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ZyVersa Therapeutics Inc. is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates which address high unmet medical needs in the areas of renal and inflammatory diseases. The company's development pipeline includes phase 2a ready VAR 200 and IC 100. ZyVersa Therapeutics Inc., formerly known as Larkspur Health Acquisition Corp., is based in WESTON, Fla.
Fiscal Year End Date: 12/31